Abstract:Peng Guo, 1 Rui Li, 2 Tie Hua Piao, 3 Chun Lan Wang, 3 Xiao Lu Wu, 3 Hong Yan Cai 3 1 College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Changchun, 130000, People's Republic of China; 2 Graduate School, Beijing University of Chinese Medicine, Beijing, 100000, People's Republic of China; 3 Pulmonology Department, The First Clinical Hospital of Jilin Academy of Traditional Chinese Medicine, Changchun, 130000, People's Republic of China Correspondence: Hong Yan Cai, The First Clinical Hospital of Jilin Academy of Traditional Chinese Medicine, Changchun, 130000, People's Republic of China, Email Chronic obstructive pulmonary disease (COPD) includes chronic bronchitis, emphysema, and small airway obstruction. Incompletely reversible airflow limitation, inflammation, excessive mucus secretion and bronchial mucosal epithelial lesions are the main pathological basis of the disease. The prevalence of COPD is increasingly worldwide, which has caused the burden on individuals and society. This paper summarizes the pathogenesis of COPD and clarifies the effect and mechanism of the latest targeted drugs for COPD. Besides, we focus on NOD-like receptor thermal protein domain associated protein 3 inflammasome (NLRP3 inflammasome). NLRP3 can promote production of interleukin-1β (IL-1β) and interleukin-18 (IL-18). NLRP3 is an important factor in the migratory aggregation of macrophages and neutrophils and the generation of oxidative stress. Inhibition of NLRP3 inflammasome indirectly blocks the inflammatory effects of IL-1β and IL-18, which may be regarded as an ideal target for COPD treatment. Keywords: chronic obstructive pulmonary disease, pathogenesis, targeted drugs, NLRP3 COPD is an incurable chronic lung disease, which is also complicated by pulmonary heart disease and respiratory failure in some individuals with a tremendous burden on individuals and society. At present, it is not clear whether the pathological mechanisms of COPD are mainly thought to be the result of genetic and environmental interactions. Moreover, smoking is considered to be the main environmental factor to trigger COPD. 1–3 Except for genetics, gender, 4 occupation, 4,5 airway hyperresponsiveness, 6 lung growth and development, 3,7 and infection 8 also play an important role in the development of COPD. It is easily understood that gender may influence the history of smoking and the particulate environment in which the occupation is located. However, the status of lung growth and development determines the susceptibility to COPD, which seems to have a close relationship with genetics. 9,10 We should focus on airway hyperreactivity, which is an independent predictor of COPD and can exist independently without asthma and bronchitis, suggesting that the inflammatory response in COPD is different from asthma. 6,11 In addition to the above causes, inflammatory mechanisms, oxidative stress, and protease-antiprotease imbalance are also involved in the development of COPD. Various reasons for bronchial mucosal epithelial cell degeneration, necrosis, squamous metaplasia and recurrent injury-repair airway wall eventually lead to the occurrence of structural repeated remodeling of the airways and scar formation. 12,13 Currently, there is still no specific treatment for COPD, and palliative regimens to improve airflow limitation are the mainstay methods. We generally do not advocate drug intervention for COPD in the stable period, but in the acute attack stage, antibiotics, inhaled corticosteroids, bronchodilators, and other medicines are widely used in clinical practice. However, the negative effects of these drugs should not be ignored. For example, frequent use of inhaled corticosteroids can cause side effects such as osteoporosis, immunosuppression and increased probability of infection, especially infection that promotes the recurrence of COPD, 8,14 while bronchodilators, for example, the anticholinergic agents and β2 agonists commonly used in clinical practice have side effects such as heart rate disturbance, impact on vision, urinary retention, and metabolic disorders, which cannot be ignored. 15,16 With the development of molecular biology, targeted drugs for treatment by blocking COPD development are gradually being developed. This paper not only reviews the pathogenesis of COPD and the pharmacological mechanisms of COPD-related targeted drugs but also elaborates the concerned contribution of NLRP3 to COPD and the effectiveness of NLRP3 inhibitors and related advances. Oxidative stress is involved in the development of several inflammatory conditions and is an important pathogenetic factor in COPD. Sti -Abstract Truncated-

Andrographolide Attenuates NLRP3 Inflammasome Activation and Airway Inflammation in Exacerbation of Chronic Obstructive Pulmonary Disease

Association of NLRP3 inflammasome signaling pathway with progression of chronic obstructive pulmonary disease

NLRP3 Inflammasome Involves in the Acute Exacerbation of Patients with Chronic Obstructive Pulmonary Disease

Inhibitory Effect of P22077 on Airway Inflammation in Rats with COPD and Its Mechanism

Andrographolide alleviates bleomycin-induced NLRP3 inflammasome activation and epithelial-mesenchymal transition in lung epithelial cells by suppressing AKT/mTOR signaling pathway

Pathological Mechanism and Targeted Drugs of COPD

Effect and its clinical significance of different dose of glucocorticoids on inflammation mediators in patients with acute exacerbation of chronic obstructive pulmonary diseases

Andrographolide Sulfonate Ameliorates Lipopolysaccharide-Induced Acute Lung Injury in Mice by Down-Regulating MAPK and NF-κB Pathways.

Andrographolide ameliorates OVA-induced lung injury in mice by suppressing ROS-mediated NF-κB signaling and NLRP3 inflammasome activation.

[Effects of Andrographolide on the Expression of Eosinophil Granulocytes and Possible Mechanisms].

Alleviatory Role of Panax Notoginseng Saponins in Modulating Inflammation and Pulmonary Vascular Remodeling in Chronic Obstructive Pulmonary Disease: mechanisms and Implications

Effects of acetylcysteine on micro-inflammation and pulmonary ventilation in chronic obstructive pulmonary disease exacerbation

Platelet-to-Lymphocyte Ratio (PLR), Neutrophil-to-Lymphocyte Ratio (NLR), Monocyte-to-Lymphocyte Ratio (MLR), and Eosinophil-to-Lymphocyte Ratio (ELR) as Biomarkers in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

Syk-Targeted, a New 3-Arylbenzofuran Derivative EAPP-2 Blocks Airway Inflammation of Asthma–COPD Overlap in vivo and in vitro

The Efficacy & Molecular Mechanisms of a Terpenoid Compound Ganoderic Acid C1 on Corticosteroid-Resistant Neutrophilic Airway Inflammation: In vivo and in vitro Validation

Targeting TLR4 and regulating the Keap1/Nrf2 pathway with andrographolide to suppress inflammation and ferroptosis in LPS-induced acute lung injury

Development and in vitro-in vivo performances of an inhalable andrographolide dry powder to target pulmonary inflammation

Andrographolide sulfonate attenuates alveolar hypercoagulation and fibrinolytic inhibition partly via NF-κB pathway in LPS-induced acute respiratory distress syndrome in mice

Efficacy of Acupuncture in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

Effects of Empirical Glucocorticoid Use on Severe Acute Exacerbation of COPD During Hospitalization